CorMedix Inc. (CRMD) earnings date
Mar 18, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 10% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 16 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | before open | 43 | 8-K |
| Q2 FY2026 | Thu, Aug 13, 2026 | before open | 44 | 8-K |
| Q1 FY2026 | Thu, May 14, 2026 | before open | 44 | 8-K |
| Q4 FY2025 | Thu, Mar 5, 2026 | before open | 64 | 8-K |
| Q3 FY2025 | Wed, Nov 12, 2025 | before open | 43 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q1 FY2025 | Tue, May 6, 2025 | before open | 36 | 8-K |
| Q4 FY2024 | Tue, Mar 25, 2025 | before open | 84 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 CORMEDIX THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Recently announced acquisition of assets of Heron Therapeutics ‒ ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million ; Adjusted EBITDA of $3.1 million ‒ ‒ Company maintains FY 2026 revenue and narrows Adjusted EBITDA guidance ‒ ‒ Conference call scheduled for today at 8:30 a.m. Eastern Time ‒ Parsippany, NJ – November 12, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the third quarter ended September 30, 20" exhibit |
| Q3 FY2026 | "CorMedix believes the transaction will be immediately accretive to earnings and free cash flow upon closing, which it anticipates in the first quarter of 2027, subject to approval by Heron’s stockholders, regulatory clearance and other customary closing conditions." exhibit |
| Q3 FY2026 | "The Company anticipates agency action on the application in the first quarter of 2027." exhibit |
| Q3 FY2026 | "The Company maintains full-year 2026 consolidated revenue guidance of $325 to $345 million, narrows full-year adjusted EBITDA guidance to a range of $130 to $140 million from a range of $125 to $140 million, and reduces cash-based OpEx guidance to a range of $140 to $145 million from $145 to $155 million." exhibit Read from the sentence: revenue $325 million to $345 million, FY2026 |
| Q3 FY2026 | "In light of recently announced changes to the CMS reimbursement framework, the Company believes it is appropriate to suspend any previously issued 2027 DefenCath revenue guidance and defer future guidance until early 2027." exhibit |
| Q3 FY2026 | "CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position" exhibit |
| Q3 FY2026 | "Parsippany, NJ – November 2, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the Company’s complete quarterly financial performance." exhibit |
| Q3 FY2026 | "CorMedix reaffirms its August 2026 total revenue guidance of between
$325 million and $345 million for the full-year 2026." exhibit Read from the sentence: revenue $325 million to $345 million, FY2026 |
| Q3 FY2026 | "Based on CorMedix evaluation of sales data and insights that the Company has in connection with DefenCath fee-for-service utilization, including terms of its contractual arrangements with customers, the Company anticipates that the DefenCath Add-on will decline in Q2 of 2027 compared to Q1, but increase in Q3 and/or Q4 of 2027 compared to Q2, subject to how CMS applies certain utilization data." exhibit |
| Q3 FY2026 | "CorMedix expects to hold a conference call on November 12, 2026 to discuss its financial results and additional business updates at that time." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CRMD
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CRMD
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/CRMD/"><img src="https://veritasdata.dev/embed/CRMD.svg" alt="CRMD earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/CRMD/)
Script
<script async src="https://veritasdata.dev/embed/CRMD.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CRMD"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.